綠葉製藥(02186.HK):博安生物向香港聯交所提交上市申請
格隆匯5月13日丨綠葉製藥(02186.HK)宣佈,於2022年5月13日,博安生物向香港聯交所提交上市申請,藉以申請批准博安生物H股於香港聯交所主板上市及買賣。
博安生物擬以全球發售方式進行股份發售,惟全球發售的詳情有待落實。截至公吿日期,博安生物由公司間接擁有72.32%權益。於建議分拆完成後,博安生物擬繼續作為公司的附屬公司。
博安生物是一家全面綜合性生物製藥公司,致力於中國及全球開發、製造及商業化適用於各個治療領域的高質量生物製劑。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.